MX2018015022A - Métodos para el tratamiento de la enfermedad de alzheimer. - Google Patents

Métodos para el tratamiento de la enfermedad de alzheimer.

Info

Publication number
MX2018015022A
MX2018015022A MX2018015022A MX2018015022A MX2018015022A MX 2018015022 A MX2018015022 A MX 2018015022A MX 2018015022 A MX2018015022 A MX 2018015022A MX 2018015022 A MX2018015022 A MX 2018015022A MX 2018015022 A MX2018015022 A MX 2018015022A
Authority
MX
Mexico
Prior art keywords
disease
methods
treating alzheimer
subject
amyloid
Prior art date
Application number
MX2018015022A
Other languages
English (en)
Spanish (es)
Inventor
Joseph Sevigny Jeffrey
Lugene Williams Leslie
Phillip Boot Brendon
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of MX2018015022A publication Critical patent/MX2018015022A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2018015022A 2016-06-07 2017-06-06 Métodos para el tratamiento de la enfermedad de alzheimer. MX2018015022A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346818P 2016-06-07 2016-06-07
US201662435531P 2016-12-16 2016-12-16
PCT/EP2017/063711 WO2017211827A1 (en) 2016-06-07 2017-06-06 Methods for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2018015022A true MX2018015022A (es) 2019-08-14

Family

ID=59067640

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015022A MX2018015022A (es) 2016-06-07 2017-06-06 Métodos para el tratamiento de la enfermedad de alzheimer.

Country Status (12)

Country Link
US (2) US20200308259A1 (enExample)
EP (1) EP3464350A1 (enExample)
JP (3) JP2019517540A (enExample)
KR (2) KR20230165883A (enExample)
CN (3) CN114796481A (enExample)
AU (2) AU2017276656A1 (enExample)
BR (1) BR112018075300A2 (enExample)
CA (1) CA3026598A1 (enExample)
IL (1) IL263433B2 (enExample)
MA (1) MA45149A (enExample)
MX (1) MX2018015022A (enExample)
WO (1) WO2017211827A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3696192A1 (en) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
US11236155B2 (en) 2019-03-26 2022-02-01 Janssen Pharmaceutica Nv Antibodies to pyroglutamate amyloid-β and uses thereof
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
WO2021081101A1 (en) * 2019-10-22 2021-04-29 Biogen Ma Inc. Anti-beta-amyloid antibody for treating alzheimer's disease
BR112023001061A2 (pt) 2020-07-23 2023-04-04 Othair Prothena Ltd Anticorpos antiabeta
KR102321601B1 (ko) * 2020-11-19 2021-11-05 주식회사 휴런 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법
WO2022261026A2 (en) * 2021-06-07 2022-12-15 Biogen Ma Inc. Methods for treating alzheimer's disease
US20250122146A1 (en) * 2021-09-30 2025-04-17 The Scripps Research Institute Compounds for reducing neuroinflammation
IL312715A (en) * 2021-11-19 2024-07-01 Ap Biosciences Inc Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160049045A (ko) * 2006-07-14 2016-05-04 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
CN101622275B (zh) 2007-01-05 2013-11-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
CA2813493C (en) 2010-10-11 2019-07-09 University Of Zurich Human anti-tau antibodies
RU2651486C2 (ru) * 2012-10-15 2018-04-19 Медиммьюн Лимитед Антитела к бета-амилоиду
CA2894178A1 (en) * 2012-12-07 2014-06-12 Biogen International Neuroscience Gmbh A method of reducing brain amyloid plaques using anti-a.beta. antibodies
SG10201705104UA (en) 2012-12-21 2017-07-28 Biogen Int Neuroscience Gmbh Human anti-tau antibodies
BR112016018170A2 (pt) * 2014-02-08 2018-02-20 Genentech, Inc. métodos para tratar doença de alzheimer
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer

Also Published As

Publication number Publication date
US20220281963A1 (en) 2022-09-08
JP2025160337A (ja) 2025-10-22
US20200308259A1 (en) 2020-10-01
EP3464350A1 (en) 2019-04-10
KR20230165883A (ko) 2023-12-05
AU2024216442A1 (en) 2024-10-17
WO2017211827A1 (en) 2017-12-14
JP2019517540A (ja) 2019-06-24
CN109476730A (zh) 2019-03-15
AU2017276656A1 (en) 2018-12-13
IL263433A (en) 2019-01-31
CN114796481A (zh) 2022-07-29
CA3026598A1 (en) 2017-12-14
IL263433B2 (en) 2024-03-01
CN114931635A (zh) 2022-08-23
IL263433B1 (en) 2023-11-01
KR20190021311A (ko) 2019-03-05
JP2022145965A (ja) 2022-10-04
MA45149A (fr) 2019-04-10
BR112018075300A2 (pt) 2019-04-30

Similar Documents

Publication Publication Date Title
MX2018015022A (es) Métodos para el tratamiento de la enfermedad de alzheimer.
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
CL2017000156A1 (es) Procedimientos para el tratamiento de paramixovirus.
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX388325B (es) Metodos de diagnostico para tratamiento con linfocitos t.
MX2017016806A (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina.
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
CL2021001389A1 (es) Formulaciones en cápsula
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2017003513A (es) Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
CO2020005485A2 (es) Administración oral de análogos del péptido glp-1
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
MX389474B (es) Dimetilfumarato y regimenes de vacunacion.
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato